Technical Analysis for INO - Inovio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 8.57 -0.70% -0.06
INO closed down 0.7 percent on Wednesday, June 16, 2021, on 37 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical INO trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -0.70%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.70%
Wide Bands Range Expansion -0.70%
Older End-of-Day Signals for INO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 3 hours ago
60 Minute Opening Range Breakdown about 4 hours ago
Possible NR7 about 4 hours ago
Rose Above 10 DMA about 7 hours ago
10 DMA Resistance about 8 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Inovio Pharmaceuticals, Inc. Description

Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company's DNA-based SynCon technology enables the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. Inovio Pharmaceuticals, Inc. has collaboration and license agreements with VGX International, Merck, and ChronTech. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Infectious Diseases Cancers Prostate Cancer Clinical Research Influenza Coronavirus Vaccine Vaccination Hepatitis B Leukemia Hepatitis C Immunodeficiency Hepatitis B Virus Hepatitis C Virus Influenza Vaccine Virology Virus Malaria Cervical Cancer Papillomavirus Avian Influenza Electroporation Seasonal/Pandemic Influenza Universal Flu Vaccine

Is INO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 33.79
52 Week Low 5.81
Average Volume 8,881,889
200-Day Moving Average 10.40
50-Day Moving Average 7.74
20-Day Moving Average 8.02
10-Day Moving Average 8.73
Average True Range 0.55
ADX 31.9
+DI 33.12
-DI 14.43
Chandelier Exit (Long, 3 ATRs) 8.68
Chandelier Exit (Short, 3 ATRs) 8.20
Upper Bollinger Bands 9.72
Lower Bollinger Band 6.32
Percent B (%b) 0.66
BandWidth 42.39
MACD Line 0.41
MACD Signal Line 0.31
MACD Histogram 0.0999
Fundamentals Value
Market Cap 1.45 Billion
Num Shares 169 Million
EPS -1.22
Price-to-Earnings (P/E) Ratio -7.05
Price-to-Sales 803.76
Price-to-Book 6.50
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.22
Resistance 3 (R3) 9.21 9.00 9.11
Resistance 2 (R2) 9.00 8.83 9.00 9.07
Resistance 1 (R1) 8.78 8.73 8.89 8.79 9.04
Pivot Point 8.57 8.57 8.62 8.57 8.57
Support 1 (S1) 8.35 8.40 8.46 8.36 8.10
Support 2 (S2) 8.14 8.30 8.14 8.07
Support 3 (S3) 7.92 8.14 8.03
Support 4 (S4) 7.93